Abstract:Introduction Acute myeloid leukemia (AML) is a molecular heterogeneous disease that originates from the malignant transformation of a hematogenic stem- or progenitor cells resulting in a leukemia stem cell (LSC). LSCs are a main cause of resistance to therapy and relapse. Despite recent advances in targeted therapy and immunotherapy, prognosis for elderly patients not fit do undergo intensive therapy remains poor. We recently documented that targeting CD70, the ligand of the tumor necrosis factor receptor (TNFR) CD27, by the antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced monoclonal antibody (mAb) cusatuzumab eliminates LSC. We now studied the role of the related TNFR lymphotoxin b receptor (LTbR) with its ligand LIGHT in the pathogenesis of AML in mice and humans and developed a LIGHT targeting mAb to specifically eliminate LSCs. Experimental design We investigated the impact of LIGHT/LTbR signalling in AML development by using the retrovirally-induced MLL-AF9 syngeneic AML mouse model. Light-, Ltbr -deficient and control MLL-AF9 transduced LSCs were injected intravenously into non-irradiated BL/6 recipient mice. AML development was evaluated by analysing MLL-AF9-GFP-positive leukemic cells in blood, spleen, and bone marrow (BM). BM LSC were phenotypically characterized by FACS and functionally by performing colony forming unit (CFU) assays in vitro and by secondary transplantations of LSCs including limited dilution assays (LDA) in vivo. Correlative survival analysis for LIGHT and LTbR expression was performed on a publicly available gene dataset (GSE6891). LIGHT and LTBR protein expression was analysed on primary AML CD34 + leukemic stem and progenitor cells (LSPCs) and control human CD34 + hematopoietic stem cell and progenitor cells (HSCPs). LIGHT/LTbR signalling was blocked by either siRNA treatment or by treatment with novel LIGHT-targeting mAb. The effect of blocking LIGHT/LTbR-signalling was analysed in vitro by CFU assays, RNA-sequencing and xenotransplant experiments in vivo. LIGHT-targeting mAbs were generated by immunization of llamas and phage display selections followed by cloning of FABs into a human backbone (hIgG1). Clones were selected based on their blocking potency of receptor/ligand interaction using competition ELISA and FACS-based cell binding affinity assays. ADCC-enhanced anti-LIGHT mAbs were generated via POTELLIGENT® technology. Anti-LIGHT mAbs that specifically block the interaction of LIGHT/LTBR with deficiency in effector functions (Fc-death) were produced by amino acid substitutions in the CH2 domain of the parental clone. Results LTbR was expressed by HSCs and AML LSCs. In contrast, LIGHT was only expressed on murine and human LSCs but not normal HSCs. The absence of LIGHT or its receptor LTbR on LSCs resulted in significantly prolonged survival and decreased numbers of LSC in BM of AML mice. Light -/- and Ltbr -/- LSCs had a reduced CFU capacity compared to control LSCs. Similarly, inhibition of LIGHT-signalling on LSCs via LTbR-Ig significantly reduced colony formation. Moreover, secondary transplantation of Light -/-LSCs resulted in prolonged survival compared to Light-proficient LSCs. An LDA analysis revealed a 11-fold reduction of the LSC frequency in BM in the absence of LIGHT or LTBR. Similarly, inhibiting LIGHT signalling by siLIGHT RNA in human AML LSPCs resulted in reduced CFU capacity compared to control siRNA treatment. In addition, a GEO analysis revealed that low LIGHT or LTbR mRNA levels correlated with improved overall survival in AML patients. After immunizations of llamas and phage-display selection three humanized anti-LIGHT mAbs with high blocking and high binding efficiency were selected (mAb10F11 and 12C2 specific for human LIGHT and the cross-reactive murine/human 9F6 mAB). Incubation of LSCs with the blocking mAbs significantly reduced CFU capacity. HSPCs from healthy donors remained unaffected by the treatment. A gene expression analysis revealed that blocking LIGHT/LTbR-signalling in LSCs reduced stemness and promoted differentiation. In addition, ADCC-enhanced mAbs activated NK cells to eliminate LIGHT-expressing LSCs. Our findings reveal that LIGHT/LTbR-signalling is crucial for the pathogenesis of AML and especially for the maintenance and expansion of LSCs. We developed and validated novel LIGHT targeting mAbs in vitro and in vivo for further development in clinical trials.

A Novel Approach to Generate LIGHT Mutants with Selectivity to Binding Partners (TECH2P.925)

Mechanistic Basis for Functional Promiscuity in the TNF and TNF Receptor Superfamilies: Structure of the LIGHT:DcR3 Assembly.

Exploration and blockade of the decoy strategy: crystal structure of the LIGHT:DcR3 complex and rational design of DcR3 antagonists

HVEM Structures and Mutants Reveal Distinct Functions of Binding to LIGHT and BTLA/CD160

The Complementation of Lymphotoxin Deficiency with LIGHT, a Newly Discovered TNF Family Member, for the Restoration of Secondary Lymphoid Structure and Function.

The Regulation of T Cell Homeostasis and Autoimmunity by T Cell–derived LIGHT

Light (A Cellular Ligand For Herpes Virus Entry Mediator And Lymphotoxin Receptor)-Mediated Thymocyte Deletion Is Dependent On The Interaction Between Tcr And Mhc/Self-Peptidel

Immunoregulation by tumor necrosis factor superfamily member LIGHT.

The critical role of LIGHT, a TNF family member, in T cell development.

Modulation of T-cell-mediated Immunity in Tumor and Graft-Versus-host Disease Models Through the LIGHT Co-Stimulatory Pathway.

Allosteric regulation of binding specificity of HVEM for CD160 and BTLA ligands upon G89F mutation

Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.

Molecular Cloning and Characterization of TNFSF14 (LIGHT) and Its Receptor TNFRSF14 (HVEM) in Guinea Pig (cavia Porcellus).

The Role of LIGHT in T Cell-Mediated Immunity

Monoclonal Antibodies Targeting LIGHT Block Ltbr Signalling and Eliminate Acute Myeloid Leukemia Stem Cells

Promoting Immune Responses by LIGHT in the Face of Abundant Regulatory T Cell Inhibition

Selective Targeting of the LIGHT-HVEM Costimulatory System for the Treatment of Graft-Versus-host Disease

Crystal structures of FasL:DcR3 and LIGHT:DcR3 complexes reveal the molecular basis for the broad specificity of DcR3 (CCR5P.255)

Multilayered Computational Framework for Designing Peptide Inhibitors of HVEM-LIGHT Interaction

Essential Role of TNF Family Molecule LIGHT As a Cytokine in the Pathogenesis of Hepatitis

Targeting tumors with LIGHT to generate metastasis-clearing immunity.